Cargando…

ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with high morbidity and mortality. Therefore, it is very important to find potential biomarkers that can effectively predict the prognosis and progression of HCC. Recent studies have shown that anti-silencing function 1B (ASF1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Xiaoxi, Lv, Longxian, Zhao, Yalei, Zhang, Fen, Hu, Qingqing, Li, Zuhong, Zhu, Danhua, Li, Lanjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787347/
https://www.ncbi.nlm.nih.gov/pubmed/35087760
http://dx.doi.org/10.3389/fonc.2021.801506
_version_ 1784639343376203776
author Ouyang, Xiaoxi
Lv, Longxian
Zhao, Yalei
Zhang, Fen
Hu, Qingqing
Li, Zuhong
Zhu, Danhua
Li, Lanjuan
author_facet Ouyang, Xiaoxi
Lv, Longxian
Zhao, Yalei
Zhang, Fen
Hu, Qingqing
Li, Zuhong
Zhu, Danhua
Li, Lanjuan
author_sort Ouyang, Xiaoxi
collection PubMed
description Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with high morbidity and mortality. Therefore, it is very important to find potential biomarkers that can effectively predict the prognosis and progression of HCC. Recent studies have shown that anti-silencing function 1B (ASF1B) may be a new proliferative marker for tumor diagnosis and prognosis. However, the expression and function of ASF1B in hepatocellular carcinoma remain to be determined. In this study, integrated analysis of the Cancer Genome Atlas (TCGA), genotypic tissue expression (GTEx), and Gene Expression Omnibus (GEO) databases revealed that ASF1B was highly expressed in HCC. Kaplan-Meier survival curve showed that elevated ASF1B expression was associated with poor survival in patients with liver cancer. Correlation analysis of immune infiltration suggested that ASF1B expression was significantly correlated with immune cell infiltration in HCC patients. Gene set enrichment analysis (GSEA) indicated that ASF1B regulated the cell cycle, DNA Replication and oocyte meiosis signaling. Our experiments confirmed that ASF1B was highly expressed in HCC tissues and HCC cell lines. Silence of ASF1B inhibited hepatocellular carcinoma cell growth in vitro. Furthermore, ASF1B deficiency induced apoptosis and cell cycle arrest. Mechanistically, ASF1B knockdown reduced the expression of proliferating cell nuclear antigen (PCNA), cyclinB1, cyclinE2 and CDK9.Moreover, ASF1B interacted with CDK9 in HCC cells. Taken together, these results suggest that the oncogenic gene ASF1B could be a target for inhibiting hepatocellular carcinoma cell growth.
format Online
Article
Text
id pubmed-8787347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87873472022-01-26 ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma Ouyang, Xiaoxi Lv, Longxian Zhao, Yalei Zhang, Fen Hu, Qingqing Li, Zuhong Zhu, Danhua Li, Lanjuan Front Oncol Oncology Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with high morbidity and mortality. Therefore, it is very important to find potential biomarkers that can effectively predict the prognosis and progression of HCC. Recent studies have shown that anti-silencing function 1B (ASF1B) may be a new proliferative marker for tumor diagnosis and prognosis. However, the expression and function of ASF1B in hepatocellular carcinoma remain to be determined. In this study, integrated analysis of the Cancer Genome Atlas (TCGA), genotypic tissue expression (GTEx), and Gene Expression Omnibus (GEO) databases revealed that ASF1B was highly expressed in HCC. Kaplan-Meier survival curve showed that elevated ASF1B expression was associated with poor survival in patients with liver cancer. Correlation analysis of immune infiltration suggested that ASF1B expression was significantly correlated with immune cell infiltration in HCC patients. Gene set enrichment analysis (GSEA) indicated that ASF1B regulated the cell cycle, DNA Replication and oocyte meiosis signaling. Our experiments confirmed that ASF1B was highly expressed in HCC tissues and HCC cell lines. Silence of ASF1B inhibited hepatocellular carcinoma cell growth in vitro. Furthermore, ASF1B deficiency induced apoptosis and cell cycle arrest. Mechanistically, ASF1B knockdown reduced the expression of proliferating cell nuclear antigen (PCNA), cyclinB1, cyclinE2 and CDK9.Moreover, ASF1B interacted with CDK9 in HCC cells. Taken together, these results suggest that the oncogenic gene ASF1B could be a target for inhibiting hepatocellular carcinoma cell growth. Frontiers Media S.A. 2022-01-11 /pmc/articles/PMC8787347/ /pubmed/35087760 http://dx.doi.org/10.3389/fonc.2021.801506 Text en Copyright © 2022 Ouyang, Lv, Zhao, Zhang, Hu, Li, Zhu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ouyang, Xiaoxi
Lv, Longxian
Zhao, Yalei
Zhang, Fen
Hu, Qingqing
Li, Zuhong
Zhu, Danhua
Li, Lanjuan
ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma
title ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma
title_full ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma
title_fullStr ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma
title_full_unstemmed ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma
title_short ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma
title_sort asf1b serves as a potential therapeutic target by influencing cell cycle and proliferation in hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787347/
https://www.ncbi.nlm.nih.gov/pubmed/35087760
http://dx.doi.org/10.3389/fonc.2021.801506
work_keys_str_mv AT ouyangxiaoxi asf1bservesasapotentialtherapeutictargetbyinfluencingcellcycleandproliferationinhepatocellularcarcinoma
AT lvlongxian asf1bservesasapotentialtherapeutictargetbyinfluencingcellcycleandproliferationinhepatocellularcarcinoma
AT zhaoyalei asf1bservesasapotentialtherapeutictargetbyinfluencingcellcycleandproliferationinhepatocellularcarcinoma
AT zhangfen asf1bservesasapotentialtherapeutictargetbyinfluencingcellcycleandproliferationinhepatocellularcarcinoma
AT huqingqing asf1bservesasapotentialtherapeutictargetbyinfluencingcellcycleandproliferationinhepatocellularcarcinoma
AT lizuhong asf1bservesasapotentialtherapeutictargetbyinfluencingcellcycleandproliferationinhepatocellularcarcinoma
AT zhudanhua asf1bservesasapotentialtherapeutictargetbyinfluencingcellcycleandproliferationinhepatocellularcarcinoma
AT lilanjuan asf1bservesasapotentialtherapeutictargetbyinfluencingcellcycleandproliferationinhepatocellularcarcinoma